SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Building a rocket. Halftone hands assemble a rocket shaped puzzle. Concept of a startup, new business. Hasty rocket launch. Innovation, teamwork, development of ideas and technologies
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for sickle cell/beta thalassemia gene-editing therapy Casgevy.
September 2, 2025
 · 
2 min read
 · 
Heather McKenzie
Exeternal view of the Servier's headquarters in France
Cancer
Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA
The French giant is gaining access to darovasertib, a small molecule protein kinase C inhibitor already in Phase II/III trials, with rights for the whole world besides the U.S.
September 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Illustration showing a handshake, signaling cooperation, goodwill
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
 · 
1 min read
 · 
Annalee Armstrong
2D illustration of the gut with microorganisms
Inflammatory bowel disease
Roche Makes Preclinical IBD Play in $420M+ OMass Pact
The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A therapy the pharma obtained from its $7.1 billion acquisition of Telavant in 2023.
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Sep 17, 2020 Fremont / CA / USA - Novo Nordisk headquarters in Silicon Valley; Novo Nordisk A/S is a Danish multinational pharmaceutical company
Cardiovascular disease
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Brain neuro cell growth or damaging drawing with texture shading illustration isolated on dark background
Approvals
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII
Obesity
Lilly Ends Two Mid-Stage Trials for Second Oral Obesity Asset
While Eli Lilly’s orforglipron is full speed ahead for a regulatory filing this year, the pharma is also pushing forward with one more Phase II study of naperiglipron, which uses the same scaffold as Pfizer’s failed obesity drugs danuglipron and lotiglipron.
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
Regulatory
Rare Diseases Secure Four FDA Firsts in August
Aside from the rare disease market, Novo Nordisk also scored a key regulatory win last month for its blockbuster GLP-1 drug Wegovy, which can now be used to treat patients with metabolic dysfunction-associated steatohepatitis.
September 2, 2025
 · 
6 min read
 · 
Tristan Manalac
Hand holding a puzzle piece shaped like a brain, sunlight shining through in a forest setting.
ALS
New Wave of ALS Therapies Signals Renaissance After Incremental Regression
After a demoralizing period punctuated by the withdrawal of one of the few marketed therapies for ALS, investment in new biotechs, state-backed collaborative initiatives and buzz at BIO2025 suggest a new day in drug development for one of medicine’s most intractable diseases.
September 2, 2025
 · 
6 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS